SCHEMBL3066693

SCHEMBL3066693

CCC(CCCC(=O)N1CCCCCC1)(C(=O)N1CCCCCC1)c1cccc(NS(=O)(=O)c2ccc(OC)c(OC)c2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.45
TP53 P04637 1/20 0.45
LMNA P02545 5/20 0.44
TSHR P16473 3/20 0.43
CYP3A4 P08684 2/20 0.43
PKM P14618 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
CA12 O43570 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3066511 0.72 ALDH1A1 (0.49) ALDH1A1TP53LMNACYP2C19HDAC4
SCHEMBL6827768 0.69 ALDH1A1 (0.57) ALDH1A1LMNATSHRCYP3A4PKM
SCHEMBL6925728 0.68 ALDH1A1 (0.56) ALDH1A1LMNATSHRCYP3A4PKM
SCHEMBL3069113 0.68 ALDH1A1 (0.60) ALDH1A1LMNATSHRCYP3A4PKM
SCHEMBL6924871 0.68 ALDH1A1 (0.55) ALDH1A1LMNATSHRCYP3A4PKM
SCHEMBL6923782 0.68 ALDH1A1 (0.55) ALDH1A1LMNATSHRCYP3A4PKM
SCHEMBL3066690 0.68 ALDH1A1 (0.55) ALDH1A1LMNATSHRCYP3A4PKM
SCHEMBL6929296 0.67 ALDH1A1 (0.58) ALDH1A1LMNATSHRCYP3A4PKM
SCHEMBL3069429 0.67 ALDH1A1 (0.49) ALDH1A1LMNAKMT2AHTTSMN1; SMN2
SCHEMBL3063907 0.66 ALDH1A1 (0.44) ALDH1A1LMNAPKMKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. 2010-10-28 US disclosed
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US disclosed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US disclosed
EP-1922313-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS Laboratorios Almirall, S.A. (ES) 2008-05-21 EP disclosed
WO-2007017096-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. (ES) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists ADORA2B, ADORA2A, ADORA3 ALDH1A1 734/4885TP53 2229/4885LMNA 3415/4885
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS ADORA2B, ADORA2A, ADORA1 ALDH1A1 742/4885TP53 4229/4885LMNA 3402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.